NHE9 has been implicated in multiple malignancies, including GBM, prostate cancer, colorectal cancer, esophageal squamous carcinoma, oral cancer, and ovarian cancer (reviewed in (25)). This evidence concerns the gene SLC9A9 and glioblastoma.